연구
연구업적
최근 5년 연구업적 현황
| 연도 | 2025년 | 2024년 | 2023년 | 2022년 | 2021년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 196편 | 179편 | 173편 | 163편 | 184편 |
| 공동 | 132편 | 147편 | 120편 | 115편 | 136편 | |
| 합계 | 328편 | 326편 | 293편 | 278편 | 320편 | |
1815. Dynamic cohesin-mediated chromatin architecture controls epithelial-mesenchymal plasticity in cancer.
Yun J, Song SH, Kim HP, Han SW, Yi EC, Kim TY.
EMBO Rep. 2016 Sep;17(9):1343-59. doi: 10.15252/embr.201541852. Epub 2016 Jul 27.
Link
1814. Aberrant Epigenetic Modifications of LPHN2 Function as a Potential Cisplatin-Specific Biomarker for Human Gastrointestinal Cancer.
Jeon MS, Song SH, Yun J, Kang JY, Kim HP, Han SW, Kim TY.
Cancer Res Treat. 2016 Apr;48(2):676-86. doi: 10.4143/crt.2015.153. Epub 2015 Sep 22.
Link
1813. Reduced cohesin destabilizes high-level gene amplification by disrupting pre-replication complex bindings in human cancers with chromosomal instability.
Yun J, Song SH, Kang JY, Park J, Kim HP, Han SW, Kim TY.
Nucleic Acids Res. 2016 Jan 29;44(2):558-72. doi: 10.1093/nar/gkv933. Epub 2015 Sep 29.
Link
1812. Phase I Study of Random Healthy Donor-Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors.
YaYang Y, Lim O, Kim TM, Ahn YO, Choi H, Chung H, Min B, Her JH, Cho SY, Keam B, Lee SH, Kim DW, Hwang YK, Heo DS.
Cancer Immunol Res. 2016 Mar;4(3):215-24. doi: 10.1158/2326-6066.CIR-15-0118. Epub 2016 Jan 19.
Link
1811. T/Tn immunotherapy avoiding immune deviation.
Son HY, Apostolopoulos V, Kim CW.
Int J Immunopathol Pharmacol. 2016 Dec;29(4):812-817. Epub 2016 Oct 19.
Link
1810. In vivo monitoring of transfected DNA, gene expression kinetics, and cellular immune responses in mice immunized with a human NIS gene-expressing plasmid.
Son HY, Jeon YH, Chung JK, Kim CW.
Int J Immunopathol Pharmacol. 2016 Dec;29(4):612-625. Epub 2016 Sep 9.
Link
1809. ANT2 shRNA downregulates miR-19a and miR-96 through the PI3K/Akt pathway and suppresses tumor growth in hepatocellular carcinoma cells.
Baik SH, Lee J, Lee YS, Jang JY, Kim CW.
Exp Mol Med. 2016 Mar 25;48:e222. doi: 10.1038/emm.2015.126.
Link
1808. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.
Jang JY, Kim YG, Nam SJ, Keam B, Kim TM, Jeon YK, Kim CW.
Mol Cancer Ther. 2016 Jun;15(6):1387-96. doi: 10.1158/1535-7163.MCT-15-0089. Epub 2016 Feb 16.
Link
1807. Dysregulated Wnt signalling and recurrent mutations of the tumour suppressor RNF43 in early gastric carcinogenesis.
Min BH, Hwang J, Kim NK, Park G, Kang SY, Ahn S, Ahn S, Ha SY, Lee YK, Kushima R, Van Vrancken M, Kim MJ, Park C, Park HY, Chae J, Jang SS, Kim SJ, Kim YH, Kim JI, Kim KM
J Pathol. 2016 Nov;240(3):304-314. doi: 10.1002/path.4777.
Link
1806. Estimation of Prognostic Marker Genes by Public Microarray Data in Patients with Ovarian Serous Cystadenocarcinoma.
Yang SD, Jang SS, Han JA, Park HS, Kim JI
Yonsei Med J. 2016 Jul;57(4):872-8. doi: 10.3349/ymj.2016.57.4.872.
Link